T/HBIQA 0004-2024 Active Group standards

T/HBIQA 0004-2024 Determination of Nine Tyrosine Kinase Drug Concentrations in Human Urine by High-Performance Liquid Chromatography-Tandem Mass Spectrometry

Publish Date: 2024-08-15 Implement Date: 2024-10-15 For services related to genuine standard inquiry, procurement, translation, and other related services in China, please Contact Us

Price: $ 20.00

Out of stock

Basic Information

Standard Code: T/HBIQA 0004-2024

Standard Type: Group standards

Standard Status: Active

is_force_gb: no

CCS Name: -

ICS Name: Laboratory medicine

Publish Date: 2024-08-15

Implement Date: 2024-10-15

Scope

Main technical content: This document specifies a high-performance liquid chromatography-tandem mass spectrometry method for determining the content of nine tyrosine kinase drugs in human urine. This document is applicable to the determination of the content of Tivantinib, LY2157299, Sorafenib, Lenvatinib, Regorafenib, Cabozantinib, Anlotinib, Apatinib, and Gefitinib in human urine.